(Q34070909)

30 July 2017

1 reference

title

PET studies and motor complications in Parkinson's disease (English)

1 reference

30 July 2017

Brooks DJ

1

1 reference

30 July 2017

language of work or name

1 reference

1 October 2000

1 reference

30 July 2017

published in

Trends in Neurosciences

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

10 Suppl

1 reference

30 July 2017

page(s)

S101-8

1 reference

Levodopa-induced dyskinesia: review, observations, and speculations

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Pathogenesis of dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Characterization of normal and supersensitive dopamine receptors: Effects of ergot drugs and neuropeptides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Striatal inhomogeneities and basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Dopamine autoreceptor function is lost in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Dopamine D2 receptor density remains constant in treated Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Subtraction autoradiography of opiate receptor subtypes in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Localization of opiate receptors and enkephalins in the rat striatum in relationship with the nigrostriatal dopaminergic system: lesion studies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Striatal opiate receptors: Pre- and postsynaptic localization

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Alterations in brain opiate receptors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Parkinson's disease: nigral receptor changes support peptidergic role in nigrostriatal modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Focal cortical release of endogenous opioids during reading-induced seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Self-initiated versus externally triggered movements

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Motor reorganization in acquired hemidystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Functional brain networks in DYT1 dystonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900016-1

7 January 2021

10.1016/S1471-1931(00)00016-1

Identifiers

DOI

1 reference

30 July 2017

1 reference